Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Clinical Genitourinary Cancer - Tập 15 - Trang 502-508 - 2017
Charles Van Praet1, Sylvie Rottey2, Fransien Van Hende3, Gino Pelgrims4, Wim Demey5, Filip Van Aelst6, Wim Wynendaele7, Thierry Gil8, Peter Schatteman9, Bertrand Filleul10, Denis Schallier11, Jean-Pascal Machiels12, Dirk Schrijvers13, Els Everaert14, Lionel D'Hondt15, Patrick Werbrouck16, Joanna Vermeij17, Jeroen Mebis18, Marylene Clausse19, Marika Rasschaert20
1Department of Urology, Ghent University Hospital, Ghent, Belgium
2Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium
3Department of Medical Oncology, University Hospital Leuven, Leuven, Belgium
4Department of Medical Oncology, AZ Turnhout, Turnhout, Belgium
5Department of Medical Oncology, AZ Klina, Kalmthout, Belgium
6Department of Medical Oncology, AZ Delta, Roeselare, Belgium
7Department of Medical Oncology, Imelda Hospital, Bonheiden, Belgium
8Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
9Department of Urology, Onze Lieve Vrouw Hospital, Aalst, Belgium
10Department of Medical Oncology, Hopital De Jolimont, Haine Saint Paul, Belgium
11Department of Medical Oncology, University Hospital Brussels, Jette, Belgium
12Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint Luc, Brussels, Belgium
13Department of Medical Oncology, Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim, Antwerp, Belgium
14Department of Medical Oncology, AZ Nikolaas, Sint-Niklaas, Belgium
15Department of Medical Oncology, CHU Dinant-Godinne, Yvoir, Belgium
16Department of Urology, AZ Groeninge, Kortrijk, Belgium
17Department of Medical Oncology, ZNA Jan Palfijn, Merksem, Belgium
18Department of Medical Oncology, AZ Jessa, Hasselt, Belgium
19Department of Medical Oncology, St Luc Bouge, Namur, Belgium
20Department of Medical Oncology, UZA/AZ Monica, Antwerp, Belgium

Tài liệu tham khảo

de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X

Fizazi, 2012, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 13, 983, 10.1016/S1470-2045(12)70379-0

Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 16, 152, 10.1016/S1470-2045(14)71205-7

Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506

Van Praet, 2016, Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program, Urol Oncol, 34, 254e7, 10.1016/j.urolonc.2015.12.017

Smaletz, 2002, Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration, J Clin Oncol, 20, 3972, 10.1200/JCO.2002.11.021

Armstrong, 2010, Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer, Clin Cancer Res, 16, 203, 10.1158/1078-0432.CCR-09-2514

Chi, 2016, A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel, Ann Oncol, 27, 454, 10.1093/annonc/mdv594

Fizazi, 2015, Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer, Eur Urol, 68, 42, 10.1016/j.eururo.2014.10.001

Omlin, 2013, Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms, Eur Urol, 64, 300, 10.1016/j.eururo.2012.12.029

Halabi, 2014, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 32, 671, 10.1200/JCO.2013.52.3696

Memorial Sloan Kettering Cancer Center. PSA doubling time. Available at: http://www.mskcc.org/nomograms/prostate/psa-doubling-time. Accessed: December 3, 2014.

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Caffo, 2015, Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme, BJU Int, 115, 764, 10.1111/bju.12857

Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815

Fizazi, 2016, Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials, Ann Oncol, 27, 699, 10.1093/annonc/mdv545

Bellmunt, 2016, Prior endocrine therapy impact on abiraterone acetate clinical efficacy in metastatic castration-resistant prostate cancer: post-hoc analysis of randomised phase 3 studies, Eur Urol, 69, 924, 10.1016/j.eururo.2015.10.021

Leibowitz-Amit, 2014, Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole, Eur J Cancer, 50, 2399, 10.1016/j.ejca.2014.06.004

Houede, 2015, Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France, BMC Cancer, 15, 222, 10.1186/s12885-015-1257-2

Ryan, 2015, Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA), J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.5047

Goyal, 2012, The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer, BJU Int, 110, E575, 10.1111/j.1464-410X.2012.11286.x

Nuhn, 2014, Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel, BJU Int, 114, E11, 10.1111/bju.12531

Burgio, 2014, Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone, Endocr Relat Cancer, 21, 487, 10.1530/ERC-14-0071

Thông tin
Thông tin xuất bản

Clinical Genitourinary Cancer

Tập 15

502-508

Thông tin tác giả